Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic DMMR Colorectal Cancers
In this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer will be assessed.
Colorectal Cancer
DRUG: Pembrolizumab
To assess the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancers by objective response rate (ORR), ORR according to RECIST 1.1 criteria, 2.5 years
To assess the major pathological response (MPR) in patients undergoing surgery, MPR is defined as \< 10% residual viable tumor, 2.5 years|To find biomarkers and evaluation strategies able to accurately assess complete and near-complete responses in order to pursue organ-sparing treatment, Association between changes in circulating tumor (ct)DNA and complete and near-complete responses, and risk of relapse, 2.5 years|In case of surgery, to assess post-surgical outcome and infectious complications following neoadjuvant immunotherapy, Post-surgical outcome will be assessed by pathologic evaluation, infection complications will be graded according to CTCAE V5.0, 2.5 years|To assess the date of relapse, As determined by disease recurrence or disease-related death during follow-up after surgery, 2.5 years
In this single-center, single arm, open-label, phase II study assessing the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer, 25 patients will be enrolled. All patients will be treated with pembrolizumab 200 mg intravenously on day 1 of each 3-week cycle.